ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.6998
-0.20%
Brent Oil
81.965
0.81%
Bitcoin
68,871.79
1.39%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Noticias

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ASND
FechaHoraFuenteTítuloSímboloCompañía
16/05/202415:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
14/05/202413:31GlobeNewswire Inc.Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
13/05/202407:30GlobeNewswire Inc.Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialNASDAQ:ASNDAscendis Pharma AS
09/05/202407:30GlobeNewswire Inc.Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024NASDAQ:ASNDAscendis Pharma AS
02/05/202415:01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
25/04/202415:46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
24/04/202407:30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
07/03/202410:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
04/03/202407:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
14/02/202408:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ASNDAscendis Pharma AS
07/02/202415:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:ASNDAscendis Pharma AS
07/02/202415:01GlobeNewswire Inc.Ascendis Pharma Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:ASNDAscendis Pharma AS
07/02/202407:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ASNDAscendis Pharma AS
31/01/202415:15GlobeNewswire Inc.Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024NASDAQ:ASNDAscendis Pharma AS
31/01/202415:01GlobeNewswire Inc.Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/01/202407:30GlobeNewswire Inc.New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External InvestorsNASDAQ:ASNDAscendis Pharma AS
08/01/202407:20GlobeNewswire Inc.Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries NASDAQ:ASNDAscendis Pharma AS
07/01/202416:45GlobeNewswire Inc.Ascendis Pharma Introduces Vision 2030NASDAQ:ASNDAscendis Pharma AS
07/01/202413:00PR Newswire (US)Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countriesNASDAQ:ASNDAscendis Pharma AS
28/12/202315:15GlobeNewswire Inc.Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
20/12/202307:30GlobeNewswire Inc.Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/weekNASDAQ:ASNDAscendis Pharma AS
19/12/202307:30GlobeNewswire Inc.TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
11/12/202307:30GlobeNewswire Inc.FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/11/202303:30GlobeNewswire Inc.Ascendis Pharma Announces Strategic Partnership with Teijin Limited in JapanNASDAQ:ASNDAscendis Pharma AS
20/11/202307:00GlobeNewswire Inc.Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
15/11/202307:00GlobeNewswire Inc.Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDANASDAQ:ASNDAscendis Pharma AS
07/11/202315:01GlobeNewswire Inc.Ascendis Pharma Reports Third Quarter 2023 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
31/10/202307:30GlobeNewswire Inc.Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA ResubmissionNASDAQ:ASNDAscendis Pharma AS
26/10/202307:30GlobeNewswire Inc.Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023NASDAQ:ASNDAscendis Pharma AS
16/10/202315:01GlobeNewswire Inc.Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023NASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Su Consulta Reciente

AMEX
TMSL
T Rowe Price Small mid C...
USOTC
CORBF
Global Cord Blood (CE)
LSE
56RD
Barclays 28
MRTX
TRRXITTEUSDT
TRRXITTE International
COIN
PHCETH
Pharmaceutical Commerce
COIN
HYCKRW
HYCON
COIN
HIFIIUSD
GATE
SAVGUSDT
SAVAGE Token
NASDAQ
AAXUEXX
Hsbc Usa Inc Capped Poin...
AQEU
PROM
Banco Profilo
USOTC
CMDKF
China Modern Dairy (PK)
USOTC
SULZF
Sulzer AG Winterthur (PK)
COIN
PXLPKRW
Piction Pixel
LSE
CRPS
Ishr Glbl
LSE
92CN
Hsbc Hldg. 7%
LSE
0P4F
Ford Motor
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados